<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5391">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01139450</url>
  </required_header>
  <id_info>
    <org_study_id>0417</org_study_id>
    <nct_id>NCT01139450</nct_id>
  </id_info>
  <brief_title>Study of 0417 Ointment in the Treatment of Atopic Dermatitis</brief_title>
  <official_title>Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel Group Study of 0417 Ointment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fougera Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fougera Pharmaceuticals Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>Ecuador: Public Health Ministry</authority>
    <authority>Panama: Ministry of Health</authority>
    <authority>Dominican Republic: Consejo Nacional de Bioetica en Salud</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is to assess the efficacy of 0417 Ointment in the Treatment of Atopic
      Dermatitis.

      Treatment medication will be administered as follows: Apply a thin layer of ointment to
      affected skin areas twice daily and rub in gently and completely. Study medication will be
      applied twice a day, approximately 12 hours apart, for approximately 4 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of Success Based on the Investigator's Global Evaluation at the End of Treatment</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Mean Change From Baseline in the Total Individual Clinical Signs and Symptoms Per Body Region</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Mean Change From Baseline in Pruritus</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Mean Change From Baseline in the Percentage Total Body Surface Affected (%BSA)</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">899</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test product that contains the active pharmaceutical ingredient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reference product that contains the active pharmaceutical ingredient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo that contains no active pharmaceutical ingredient</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0417</intervention_name>
    <description>Topical 0417 test product applied twice daily for 4 weeks</description>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle of 0417 test product</intervention_name>
    <description>Vehicle of 0417 test product applied twice daily for 4 weeks</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus Ointment 0.03%</intervention_name>
    <description>Reference product for 0417 test product. Apply twice daily for 4 weeks</description>
    <arm_group_label>Reference</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Atopic Dermatitis

          -  Good health with the exception of Atopic Dermatitis

          -  Percent Body Surface Area minimum requirements

        Exclusion Criteria:

          -  Subjects who are pregnant, nursing, or planning a pregnancy within the study
             participation period.

          -  Subjects who have any systemic or dermatological disorders with the exception of
             Atopic Dermatitis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fougera Pharmaceuticals Inc.</name>
      <address>
        <city>Melville</city>
        <state>New York</state>
        <zip>11747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <lastchanged_date>September 30, 2014</lastchanged_date>
  <firstreceived_date>June 7, 2010</firstreceived_date>
  <firstreceived_results_date>September 23, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic Dermatitis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Test</title>
          <description>Test product that contains the active pharmaceutical ingredient
Tacrolimus Ointment 0.03% test product applied twice daily for 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Reference</title>
          <description>Reference product that contains the active pharmaceutical ingredient
Protopic Ointment 0.03%, Reference product applied twice daily for 4 weeks</description>
        </group>
        <group group_id="P3">
          <title>Vehicle</title>
          <description>Placebo that contains no active pharmaceutical ingredient
Vehicle of Tacrolimus Ointment 0.03% applied twice daily for 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="302"/>
                <participants group_id="P2" count="297"/>
                <participants group_id="P3" count="300"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="275"/>
                <participants group_id="P2" count="272"/>
                <participants group_id="P3" count="262"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Test</title>
          <description>Test product that contains the active pharmaceutical ingredient
Tacrolimus Ointment 0.03% test product applied twice daily for 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Reference</title>
          <description>Reference product that contains the active pharmaceutical ingredient
Protopic Ointment 0.03%, Reference product applied twice daily for 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Vehicle</title>
          <description>Placebo that contains no active pharmaceutical ingredient
Vehicle of Tacrolimus Ointment 0.03% applied twice daily for 4 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="302"/>
                <measurement group_id="B2" value="297"/>
                <measurement group_id="B3" value="300"/>
                <measurement group_id="B4" value="899"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <sub_title>Age, Years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="27.74" spread="18.11"/>
                <measurement group_id="B2" value="28.8" spread="18.99"/>
                <measurement group_id="B3" value="27.6" spread="17.34"/>
                <measurement group_id="B4" value="28.0" spread="18.14"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="186"/>
                <measurement group_id="B2" value="194"/>
                <measurement group_id="B3" value="186"/>
                <measurement group_id="B4" value="566"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="116"/>
                <measurement group_id="B2" value="103"/>
                <measurement group_id="B3" value="114"/>
                <measurement group_id="B4" value="333"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="280"/>
                <measurement group_id="B2" value="275"/>
                <measurement group_id="B3" value="279"/>
                <measurement group_id="B4" value="834"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Central America</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
                <measurement group_id="B2" value="22"/>
                <measurement group_id="B3" value="21"/>
                <measurement group_id="B4" value="65"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Success Based on the Investigator’s Global Evaluation at the End of Treatment</title>
        <time_frame>4 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Test</title>
            <description>Test product that contains the active pharmaceutical ingredient
Tacrolimus Ointment 0.03% test product applied twice daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Reference</title>
            <description>Reference product that contains the active pharmaceutical ingredient
Protopic Ointment 0.03%, Reference product applied twice daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Vehicle</title>
            <description>Placebo that contains no active pharmaceutical ingredient
Vehicle of Tacrolimus Ointment 0.03% applied twice daily for 4 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="226"/>
                  <measurement group_id="O2" value="238"/>
                  <measurement group_id="O3" value="228"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Incidence of Success Based on the Investigator’s Global Evaluation at the End of Treatment</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="123"/>
                  <measurement group_id="O2" value="130"/>
                  <measurement group_id="O3" value="86"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Mean Change From Baseline in the Total Individual Clinical Signs and Symptoms Per Body Region</title>
        <time_frame>Baseline, 4 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Mean Change From Baseline in Pruritus</title>
        <time_frame>Baseline, 4 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Mean Change From Baseline in the Percentage Total Body Surface Affected (%BSA)</title>
        <time_frame>Baseline, 4 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Test</title>
          <description>Test product that contains the active pharmaceutical ingredient
Tacrolimus Ointment 0.03% test product applied twice daily for 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Reference</title>
          <description>Reference product that contains the active pharmaceutical ingredient
Protopic Ointment 0.03%, Reference product applied twice daily for 4 weeks</description>
        </group>
        <group group_id="E3">
          <title>Vehicle</title>
          <description>Placebo that contains no active pharmaceutical ingredient
Vehicle of Tacrolimus Ointment 0.03% applied twice daily for 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Severe Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Moderate Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="297"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site irritation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="297"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Angela C. Kaplan</name_or_title>
      <organization>Fougera Pharmaceuticals Inc.</organization>
      <phone>631-659-2256</phone>
      <email>angela.kaplan@sandoz.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
